Apexigen
single dose of turns cold tumor hot data presented at some | Apexigen
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
18 of 27
Related slides by other companies
Fusion Pharmaceuticals
IPO
June 2020
single dose eradicated tumors in mice | Fusion Pharmaceuticals
Mink Therapeutics
Investor Day
November 2022
car enhances infiltration of tumor specific cells to clear tumor mink | Mink Therapeutics
Alkermes
Investor Day
March 2021
immune modulation in oncology based on engineered have pleiotropic effects and can act on every phase of the cancer immunity cycle alkermes is focusing on based therapies designed to increase visibility of tumor cells to immune system increase tumor killing potential of and cells mutation fusion remove suppressive signals in the tumor modern based drugs need a high degree of engineering to reduce side effects improve enhance efficacy natural killer journal of cancer cycle | Alkermes
Alkermes
Investor Day
March 2021
artistry determined selected as recommended phase dose for artistry efficacy expansion stage selection of based on totality of data including safety and efficacy during dose phase acceptable safety and tolerability profile consistent with the anticipated pharmacological effect and that observed with intravenous dose dependent increases in cell and cell activation and minimal increase in clinical benefit stable disease observed additional artistry data to be presented at future medical meeting phase efficacy expansion initiated based on totality of dose data regulatory cell natural killer pharmacodynamic | Alkermes
Other recent decks by Apexigen
See all presentations (2 decks)
SPAC
March 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights